Christopher J. Little, Andre A. S. Dick, James D. Perkins, Evelyn K. Hsu, Jorge D. Reyes – 13 May 2020 – Despite increased numbers of donation after circulatory death (DCD) donors, pediatric DCD livers are underused. To investigate possible reasons for this discrepancy, we conducted a retrospective cohort study using 2 data sets from the Organ Procurement and Transplantation Network for all deceased liver donors and for all recipients of DCD liver transplants from March 8, 1993, to June 30, 2018.

Hilary M. DuBrock, Michael J. Krowka, Karen Krok, Kimberly Forde, Carl Mottram, Paul Scanlon, Nadine Al‐Naamani, Mamta Patel, Amber McCormick, Michael B. Fallon, Steven M. Kawut – 11 May 2020 – We investigated the prevalence of spirometric restriction in liver transplantation (LT) candidates and the clinical impacts of restriction. We performed a cross‐sectional study within the Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2) study, a multicenter prospective cohort study of patients being evaluated for LT.

Geon‐Woo Kim, Hasan Imam, Mohsin Khan, Saiful Anam Mir, Seong‐Jun Kim, Seung Kew Yoon, Wonhee Hur, Aleem Siddiqui – 11 May 2020

Jimmy Vandel, Julie Dubois‐Chevalier, Céline Gheeraert, Bruno Derudas, Violetta Raverdy, Dorothée Thuillier, Luc Gaal, Sven Francque, François Pattou, Bart Staels, Jérôme Eeckhoute, Philippe Lefebvre – 11 May 2020

Xinjun Lu, Panagiotis Paliogiannis, Diego F. Calvisi, Xin Chen – 11 May 2020 – Primary liver cancers, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), are highly lethal tumors, with high worldwide frequency and few effective treatment options. The mammalian target of rapamycin (mTOR) complex is a central regulator of cell growth and metabolism that integrates inputs from amino acids, nutrients, and extracellular signals. The mTOR protein is incorporated into two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

Lu Lu, Zheng‐Xin Wang, Wen‐Wei Zhu, Cong‐Huan Shen, Yi‐Feng Tao, Zhen‐Yu Ma, Quan‐Bao Zhang, Rui‐Dong Li, Hu‐Liang Jia, Lun‐Xiu Qin, Jin‐Hong Chen – 11 May 2020 – We assess the safety and feasibility of the left hepatic vein preferential approach (LHVPA) based on left hepatic vein (LHV) anatomy for living donor laparoscopic left lateral sectionectomy (LLLS). Data from 50 donors who underwent LLLS in Huashan Hospital from October 2016 to November 2019 were analyzed retrospectively.

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

Erin Wolf, Nicole E. Rich, Jorge A. Marrero, Neehar D. Parikh, Amit G. Singal – 8 May 2020

Anthony Myint, Myron J. Tong, Simon W. Beaven – 7 May 2020